Fig. 3
Target protein expression levels on CLL cells and in vitro and in vivo functional data. a Number of receptors for identified targets HLA-DR, CD32, CD23, CD200, CD72, and CD21 on CLL cells (n = 9 patients except HLA-DR n = 8). Cells were stained with commercially available fluorescence labelled antibodies against the identified targets at binding saturated concentrations and analyzed by flow cytometry. The number of receptors per CLL cell was calculated based on parallel staining and analysis of calibration beads. b Correlation between target identity and in vitro functional data. Results from PCD and ADCC assays were plotted against each other and color-coded based on antibody specificity. c Screening of antibodies (hIgG1) in a PDX model using CLL cells from a rituximab-resistant patient, showing the fraction of CLL cells in spleen (normalized to isotype control) after antibody treatment (mean with SEM for n = 8 mice/antibody except isotype control were n = 7). For statistical analysis all antibodies were compared with the isotype control antibody (one-way-ANOVA) using GraphPad Prism
